tiprankstipranks
Trending News
More News >

Omada Health initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of Omada Health (OMDA) with an Overweight rating and $19 price target Omada offers a “between care” patient monitoring program that combines human-led clinical care with technology to drive behavioral change and it has “ample room to grow in an underpenetrated chronic disease market,” the analyst tells investors. The firm models a roughly 24% compound annual growth rate over the next three years and EBITDA profitability in 2027, the analyst noted.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1